Latest News - Epilepsy & Seizure Disorders

Monday, October 09, 2017 | Epilepsy & Seizure Disorders, FDA Approval/Clearance, Product Launches and Updates

Next-Generation VNS System and Implantable Device Approved

LivaNova has received FDA approval for its next-generation Vagus Nerve Stimulation (VNS) Therapy Programming System for drug-resistant epilepsy. The FDA has also approved the company's SenTiv…

Read the full story

Friday, September 29, 2017 | Epilepsy & Seizure Disorders, Phase 3/4 Trials, Research and Publications

Investigational Low-Dose Fenfluramine Shows Promise in Phase 3 Trial for Dravet Syndrome

Phase 3 findings suggest that the investigational ZX008 (low-dose fenfluramine hydrochloride, Zogenix) is effective for the treatment of Dravet syndrome. The study enrolled 119 patients across sites i…

Read the full story

Friday, September 15, 2017 | Epilepsy & Seizure Disorders, FDA Approval/Clearance, Product Launches and Updates

Briviact Approved as Monotherapy for Partial-Onset Seizures

The FDA has approved a supplemental new drug application for Briviact (brivaracetam, UCB) CV as monotherapy for partial-onset (focal) seizures (POS) in patients 16 years and older with epile…

Read the full story

Thursday, September 14, 2017 | Epilepsy & Seizure Disorders, FDA Approval/Clearance, Product Launches and Updates

Aptiom Approved for Partial-Onset Seizures in Patients Four Years of Age and Older

The FDA has approved the supplemental New Drug Application (sNDA) to expand the indication for Aptiom (eslicarbazepine acetate, Sunovion) to include treatment of partial-onset seizures in childre…

Read the full story

Friday, June 30, 2017 | Epilepsy & Seizure Disorders, Product Launches and Updates

VNS Therapy Approved in Children Ages Four Years and Older with Partial Onset Refractory Seizures

The FDA has approved the VNS Therapy (LivaNova) in patients as young as four years of age with partial onset refractory seizures. Originally approved for patients ages 12 years and older, VNS The…

Read the full story

Tuesday, June 27, 2017 | Epilepsy & Seizure Disorders, Phase 3/4 Trials

Low-Dose Fenfluramine Granted Orphan Status for LGS

The FDA has granted orphan drug designation to ZX008 (Zogenix), an investigational treatment for Lennox Gastaut Syndrome (LGS). Zogenix will initiate a Phase 3 clinical trial in LGS in second half of …

Read the full story

Monday, June 12, 2017 | Epilepsy & Seizure Disorders

American Epilepsy Society Awards Investigators for Early Career Research

The American Epilepsy Society (AES) has awarded 25 early career scientists and clinicians with fellowships or grants to support their work in epilepsy research. The award recipients include pre-doctor…

Read the full story

Friday, May 26, 2017 | Epilepsy & Seizure Disorders, Phase 3/4 Trials, Research and Publications

NEJM Publishes Phase 3 Data for Epidiolex in Dravet Syndrome as Manufacturer Eyes Mid-2017 NDA Submission

The New England Journal of Medicine has published results from a Phase 3 study showing that Epidiolex (cannabidiol, GW Pharmaceuticals) reduces monthly convulsive seizure frequency compared to placebo…

Read the full story

Wednesday, May 03, 2017 | Epilepsy & Seizure Disorders, Phase 3/4 Trials, Product Launches and Updates, Research and Publications

New Data Highlight Efficacy and Safety of Brain Responsive Neuromodulation for Reduction of Seizures

Two new studies offer long-term perspective on the efficacy and safety of brain responsive neuromodulation for the reduction of seizures. One study evaluated the effects of NeuroPace’s RNS Syste…

Read the full story

Tuesday, April 25, 2017 | Epilepsy & Seizure Disorders, Research and Publications

AAN Unveils New Guideline for SUDEP at Annual Meeting

The American Academy of Neurology (AAN) and the American Epilepsy Society (AES) have released a new joint guideline for sudden unexpected death in epilepsy (SUDEP) at the AAN Annual Meeting in Boston.…

Read the full story

Friday, March 24, 2017 | Epilepsy & Seizure Disorders, Headache & Pain, Research and Publications

Review Identifies Antidepressants and AEDs Effective for Nerve Pain

A federal health agency has found certain antidepressants and anti-seizure drugs are among medications that effectively treat diabetic nerve pain. In findings published in the journal Neurology, resea…

Read the full story

Tuesday, March 14, 2017 | Epilepsy & Seizure Disorders

Sunovion Submits NDA to Expand Aptiom Indication to Pediatric Patients

Sunovion Pharmaceuticals has submitted a supplemental new drug application (sNDA) to the FDA to expand the indication for its antiepileptic drug AED Aptiom (eslicarbazepine acetate) to include use as …

Read the full story

Thursday, January 19, 2017 | Epilepsy & Seizure Disorders, Personnel/Company News, Product Launches and Updates

Takeda and Ovid Strike Partnership to Develop Investigational Agent for Rare Pediatric Epilepsy

Takeda and Ovid Therapeutics are teaming up for the clinical development and commercialization of Takeda’s investigational new drug TAK-935, a novel CH24H inhibitor, in rare pediatric epilepsies…

Read the full story

Friday, December 09, 2016 | Epilepsy & Seizure Disorders, Phase 3/4 Trials, Research and Publications

NeuroPace Unveils New Long-Term Data for Its RNS System

At the recent American Epilepsy Society Annual Meeting in Houston, NeuroPace shared new long-term data for its RNS System for the treatment of partial-onset seizure. The RNS System monitors and respon…

Read the full story

Thursday, December 08, 2016 | Epilepsy & Seizure Disorders, Phase 3/4 Trials, Research and Publications

Reflecting on New Phase 3 Epidiolex Data, GW Pharmaceuticals CEO Emphasizes Education About Cannabidiol

Greenwich Biosciences, a subsidiary of GW Pharmaceuticals, shared phase 3 data in poster presentations at the recent American Epilepsy Society Annual Meeting showing that it’s investigational ca…

Read the full story
Load More